1

TSX-V: CZO

Corporate Presentation

Forward Looking Statements

This presentation contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of product development and launches. Although the company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company’s expectations are correct.

All forward-looking statements are expressly qualified by this Cautionary Statement.

2

Overview

• Canadian leader in botanical actives innovation and

bioprocessing o Proprietary plant extraction based manufacturing process

o Active ingredients for health care and cosmetic industries

• Two active ingredients currently used in household name

products - Cosmetics & Personal Care o Beta Glucan

o Avenanthramides

• De-risked business model and robust growth strategy

support potential for significant market expansion and

revenue generation

• Near-term potential to expand into nutraceutical, OTC and

Pharma markets

3

The identification, extraction

and purification of active

compounds from natural

sources…

…which allows us to create

innovative ingredients for the

personal and healthcare

industries

…We are a Green Company!

Ceapro’s Core Expertise

4

Proprietary plant extraction based manufacturing

5

Lupinus angustifolia

And

Avena sativa

Beta Glucan Avenanthramides

Unique Bioprocessing Expertise

• Ability to isolate and purify

specific molecules from a wide

range of botanical sources

• Prototype extracts are then

prepared for bio-screening or in

vivo testing

• Unique drying (heat-free) technology for sensitive compounds

• Commercialized unique bio-actives from several botanical sources

• Ability to take concept to commercialization in a relatively short

period of time

6

New & Innovative Technologies:

“Pressurized Gas Expanded (PGX) Liquid –Spray Drying”

7

CNC before and after PGX drying

0.5 g CNC Spray Dried

0.5 g CNC PGX Dried

CNC AEROGEL Density : 0.006 g/cm3

• Production of biomaterials from different industries

Application of PGX-CNC

• Applications of PGX-CNC

• Wound healing, scaffolds

• Drug delivery

• Absorbants

• Composite-Plastics

• Paints

• PGX processing allows processing of high value biopolymers:

• Beta Glucan

• Chitosan

• Gum Arabic

• CNC

Market Sectors (Current & Future)

Cosmetics & Personal Care

• Anti-Inflammation

• Anti-Ageing

Pharma/OTC(Botanic Drugs)

• Wound Healing

• Metabolic Diseases

Nutraceuticals/Functional Foods

• Metabolic Diseases

10

Cosmetics - From Field to Formulation

11

Field

Identify

Unique

Plants

Research

Discover

Novel Functional

Actives

Manufacturing

Develop

Innovative

Processes

Consumer

Provide

Innovative

Products

Beta Glucan and Avenanthramides in Multiple Household Products

• Aveeno

• Jergens

• Lubriderm

• 3M –Nexcare

• KY Products

• Neutrogena

• Coppertone

• Dove

• Burt’s Bees

• The Body Shop

• Philosophy

• ROC

12

A Hidden Gem….

13

14

Beta glucan

Avenanthramides

Ceapro – Our Value Drivers

Beta Glucan

15

• Beta glucan is a soluble fibre found in the call walls of oat kernels

• Acts as a natural moisture barrier and film-forming agent

• Relieves and alleviates dry and itchy skin by replenishing and protecting the skin’s moisture barrier

• Provides hydration against the drying effects of the sun

• Smoothens wrinkles, reducing the visible signs of ageing

• Ceapro was the first to

demonstrate that high

molecular weight beta

glucan can penetrate human

skin.

• Dermatology applications

range from anti-ageing to

wound healing.

• New highly purified beta

glucan powder successfully

developed to address new

market demands/trends.

16

Beta Glucan in Cosmeceuticals

Natural Skin Restructuring Agent

• Proven to effectively reduces

fine lines & wrinkles

• Forms a natural barrier

protecting skin

• Wound healing agent – films

or gels

• Sustained release of active

agents requiring enhanced

percutaneous transportation

17

Avenanthramides

• Antihistamine and anti-

inflammatory properties

• Potential benefits in the

control of inflammation-

based diseases

18

Avenanthramides Clinically Proven in Cosmeceuticals

• 40% improvement in itch

perception after 1 week

• 62% of patients showed an

improvement in their skin

condition

Significant improvements in

erythema symptoms associated

in subjects with mild to

moderate atopic dermatitis

Subjects with atopy

• 89% of subjects saw

significant improvement in

itch after 1 week

• Continued improvement

after 4 weeks

19

Skin inflammation is a complex physiological process Beta glucan

• Accelerates tissue healing

• Deep hydrating agent

• Improves elasticity

• Natural film protective barrier

Avenanthramides

• Relief from itching (Pruritus)

• Reduces inflammation and swelling

• Reduces redness (Erythema)

Our Value Drivers – Advanced Skin Care

Beta glucan

Avenanthramides

20

Robust Growth Strategy

21

Cosmeceuticals

• Generate scientific data to support current product indications

• Pursue new indications for current product portfolio from research programs

• Develop new products in accordance with needs expressed by customers

• Improve manufacturing technologies

• Look for ability to develop co-products

Nutraceuticals

• Produce 2nd generations of current products (higher concentrations, powder versions, etc)

• Capture bigger margins

Pharmaceuticals

• Produce 3rd generations of current products (higher concentrations, powder versions, etc)

• Conduct formulation work and assess potential for pharmaceutical development

Beta Glucan in Nutraceuticals and Pharmaceuticals

• Potential reduction of cardiovascular and heart diseases risk

o Acts to decrease LDL and total cholesterol

• Proprietary beta glucan drug-delivery platform

o Shown to effectively penetrate into the skin, into the deep

layers as well as into the skin cells

o Uses ranging from wound care and therapy, to skin care

treatments that reduce the signs of aging

22

Avenanthramides in Nutraceuticals and Pharmaceuticals

• Avenanthramides shown to

attenuate exercise-induced

inflammation in animal studies

• Human clinical studies showed that

dietary avenanthramides

supplements significantly reduced

inflammation biomarkers in an

elderly population

• New process technology licensed

from Agriculture and Agri-Food

Canada (AAFC)

23

Value Drivers

Cosmeceuticals - Current and new indications-Base Business

Nutraceuticals - New product development-Near Term Catalyst

Pharmaceuticals - New products, new partnership discussions

Manufacturing Innovation - New processes, higher output, lower cost

24

New Bio-processing Facility

25

New 21,000 sq. ft. GMP Bio-processing Extraction

Facility in Edmonton, Alberta

• R&D

• Pilot Scale Capability

• Commercial Production

Value-Driving Milestones

26

2015 - H1 2015 - H2 2016 - H1 2016 - H2

New Manufacturing Facility

Commercial scale-up of dry powder technology platform

Ceapro in Nutraceuticals and Pharmaceuticals

Beta Glucan preclinical studies

Beta Glucan Pilot Phase

Avenanthramides Phase ½

Financial Profile - TSX-V: CZO

27

TSX-V: CZO Stock Ticker

$43,000,000 Market capitalization as of January 2, 2015

61,420,000 Common shares outstanding

$6,831,000 Total sales for the nine-month period ending September 2014

$4,000,000 Total amount of grant-based-funding raised to date

28

Financial Performance 2009-2013

-2000

0

2000

4000

6000

8000

2009 2010 2011 2012 2013

Revenue Income (loss) from Operations ($000)

29

Financial Performance First 9 months 2014 vs 2013 (in 000’s)

$0

$1 000

$2 000

$3 000

$4 000

$5 000

$6 000

$7 000

$8 000

2013 2014

Revenue Net Income

Recent Positive Momentum

30

$0,00

$0,10

$0,20

$0,30

$0,40

$0,50

$0,60

$0,70

$0,80

7-1-10 7-31-10 8-30-10 9-29-10 10-29-10 11-28-10 12-28-10

Pri

ce

Date

12/18 - Ceapro Enters

into Financing

Agreement

12/4 - Research Grant

from Alberta Innovates

Bio Solutions

11/26 - Research

Scientist Honored with

Scientific Achievement

11/14 - Third Quarter

2014 Financial Results

11/20 - Appoints

William W. Li, M.D. to

Board of Directors

7/30 - Second Quarter

2014 Financial Results

10/3 - Change of

Chairman of the Board

7/1/14 7/31/14 8/30/14 9/29/14 10/29/14 11/28/14 12/28/144

Ceapro is Poised for an Exciting 2015

A Solid Company!

Profitable

Highly-experienced, results-driven team

Operational efficiency

Solid innovative science/IP

Commercially accepted products

Expanded Marketing/Sales territories

Strong development Pipeline for long-term

sustainable growth

31

32

Thank you!

www.ceapro.com